Seeking Alpha

Shares of Idenix Pharmaceuticals (IDIX -12.2%) sink after Abbott Laboratories (ABT +0.6%)...

Shares of Idenix Pharmaceuticals (IDIX -12.2%) sink after Abbott Laboratories (ABT +0.6%) releases positive results from studies of its experimental hepatitis C treatment. Other Hep-C companies vying for a piece of the rapidly-growing multi-billion dollar market: Gilead Sciences (GILD -2.2%), Vertex Pharmaceuticals (VRTX -1.2%), Bristol-Myers Squibb (BMY -0.5%), BioCryst Pharmaceuticals (BCRX -3.4%).
Comments (1)
  • romilar
    , contributor
    Comments (625) | Send Message
     
    I would like to know where BMY stands in this hep research.Has anyone heard?
    5 Apr 2012, 12:22 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|